Canopy Biosciences, a St. Louis, MO-based provider of gene editing and gene expression products and services, acquired Zellkraftwerk GmbH, a Leipzig, Germany-based multiplex cytometry company.
Concurrent with the acquisition, Canopy closed a strategic growth investment from Ampersand Capital Partners.
Led by Jan Detmers, Zellkraftwerk leverages the ChipCytometry platform to offer complete workflow solutions—including both products and research services—for high-content cytometry on cells and tissues.
Formed in 2016 by BioGenerator, the funding arm of BioSTL in St. Louis, MO and led by Edward Weinstein, Ph.D., CEO, Canopy Biosciences has built a comprehensive platform of products and services for gene editing, gene expression analysis and regulation, and bioprocessing. Its gene editing portfolio spans CRISPR kits, off-the-shelf cell lines, as well as full service custom cell line engineering.
With the introduction of RareSeq, Canopy has added ultrasensitive DNA sequencing to its multi-omics platform including RNAseq, NanoString gene expression analysis, and multiplexed protein detection.
The company serves researchers at universities, research institutions and biotechnology and pharmaceutical companies worldwide.
The combination of Canopy and Zelkraftwerk creates a “multi-omics” company that combies genomics expertise with cell and tissue analysis solutions to support customers in drug development research and biomarker discovery.